Chinese biopharma developing recombinant protein and antibody drugs; specific product line not fully established from available knowledge.
Chinese biopharma developing recombinant protein and antibody drugs; specific product line not fully established from available knowledge.
Moat: none
Headquarters: Beijing, China · Employees: 2,200
Size Sinocelltech (688520.SS) is a China Health Care company (Biotechnology) with a market value of $1.90B, the 1220th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥27.32 on 18 Nov 2026.
Performance Over six months the shares fell 35.1%, against -3.6% for the median peer and -20.0% for the China market (cap-weighted) — lowest of 19 in its peer set.
Growth Revenue fell 39.6% over the last twelve months (peer median +13.7%); the operating margin is -75.0% (peer median -29.7%).
Valuation It trades at 13.6× enterprise value to sales against a peer median of 13.2× (8th cheapest of 15).
Capital Return on invested capital runs 30.6 points below its cost of capital (8.5% WACC).
Next results Next results expected around 28 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.14B | CN¥1.55B | CN¥2.50B | CN¥1.88B | CN¥1.02B |
| Revenue growth | — | -38% | +33% | +85% | — |
| Gross profit | CN¥1.05B | CN¥1.30B | CN¥2.25B | CN¥1.72B | CN¥924M |
| EBITDA | n/a | -CN¥259M | CN¥758M | CN¥164M | -CN¥239M |
| Net income | -CN¥958M | -CN¥565M | CN¥112M | -CN¥396M | -CN¥519M |
| Free cash flow | -CN¥555M | -CN¥490M | -CN¥248M | -CN¥886M | -CN¥976M |
| Capital expenditure | CN¥193M | CN¥217M | CN¥376M | CN¥505M | CN¥555M |
| Total debt | CN¥3.62B | CN¥3.90B | CN¥3.15B | CN¥2.75B | CN¥2.30B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688520.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -18.0% | -1.1% | 3rd lowest of 20 |
| 6-month return | -35.1% | -3.6% | lowest of 19 |
| Distance from 52-week high | -48.8% | -33.4% | 3rd lowest of 21 |
| Revenue growth (TTM) | -39.6% | +13.7% | 4th lowest of 15 |
| Operating margin | -75.0% | -29.7% | 7th lowest of 15 |
| EV / Sales | 13.6× | 13.2× | 8th cheapest of 15 |
| ROIC minus cost of capital | -30.6 pp | -8.6 pp | 2nd lowest of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Sinocelltech 688520.SS | China | $1.90B | -35% | -40% | -75% | 13.6× | n/a | n/a |
| Maravai Lifesciences MRVI | United States | $1.92B | +101% | +11% | -17% | 10.2× | n/a | n/a |
| Trevi Therapeutics TRVI | United States | $1.93B | -3% | n/a | n/a | n/a | n/a | n/a |
| BioCryst Pharmaceuticals BCRX | United States | $1.88B | -16% | +60% | 42% | 2.4× | -11.0% | +117.9% |
| Replimune REPL | United States | $1.88B | +321% | n/a | n/a | n/a | n/a | n/a |
| Septerna SEPN | United States | $1.88B | +41% | +337% | -76% | 14.7× | n/a | n/a |
| First Tracks Biotherapeutics TRAX | United States | $1.87B | +175% | n/a | n/a | n/a | n/a | n/a |
| Shenzhen Kangtai Biological Products 300601.SZ | China | $1.86B | -20% | -9% | 6% | 4.9× | 22.7% | +3.4% |
| Vera Therapeutics VERA | United States | $1.85B | -26% | n/a | -4,160% | 149.9× | n/a | n/a |
| Hemab Therapeutics COAG | United States | $1.83B | +48% | n/a | n/a | n/a | n/a | n/a |
| Immunome IMNM | United States | $1.98B | -22% | -100% | n/a | n/a | n/a | n/a |
| Lycia Therapeutics LYCA | United States | $1.81B | n/a | -55% | -593% | n/a | n/a | n/a |
| Zenas BioPharma ZBIO | United States | $1.79B | +35% | -27% | -2,748% | 146.1× | n/a | n/a |
| Aurinia Pharmaceuticals AUPH | United States | $2.03B | -5% | +21% | 45% | 5.0× | 3.5% | +41.4% |
| GemPharmatech 688046.SS | China | $1.78B | +39% | +25% | 22% | 11.7× | 33.0% | +24.8% |
| Recursion Pharmaceuticals RXRX | United States | $1.76B | -5% | +56% | -725% | 18.8× | n/a | n/a |
| Stoke Therapeutics STOK | United States | $1.75B | -12% | -86% | -913% | 50.6× | n/a | n/a |
| Evopoint Biosciences 688837.SS | China | $2.08B | n/a | n/a | n/a | 53.6× | n/a | n/a |
| Alamar Biosciences ALMR | United States | $2.12B | +51% | +195% | -42% | 26.1× | n/a | n/a |
| BGI Genomics 300676.SZ | China | $2.13B | -15% | 0% | -14% | 3.2× | n/a | n/a |
| Hugel 145020.KS | South Korea | $1.69B | -30% | +17% | 38% | 3.6× | -12.1% | +15.0% |